NCT04780217 2024-03-04
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
ImmVira Pharma Co. Ltd
Phase 1/2 Unknown
Clinical Trials
39 trialsNCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04631731 2023-06-01
ICEMELT
Western Sydney Local Health District
Phase 1/2 Unknown
NCT04652440 2023-04-19
Ablation Combined With PD-1 in HCC: Phase II Study
Sun Yat-sen University
Phase 1/2 Unknown
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT04911959 2023-02-06
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT03682276 2022-12-13
PRIME-HCC
Imperial College London
Phase 1/2 Unknown
NCT03864211 2022-09-29
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT02562963 2022-05-02
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
Tsinghua University
Phase 1/2 Unknown
NCT04233840 2022-01-27
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 1/2 Unknown
NCT04926532 2021-06-15
Toripalimab
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT04843943 2021-04-14
Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
Fudan University
Phase 1/2 Unknown
NCT03941626 2021-02-04
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03645980 2020-10-22
DKN-01 Inhibition in Advanced Liver Cancer
Johannes Gutenberg University Mainz
Phase 1/2 Unknown
NCT04538313 2020-09-04
A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
CAR-T (Shanghai) Cell Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT04162158 2019-11-14
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma
Beijing 302 Hospital
Phase 1/2 Unknown
NCT03825705 2019-10-31
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT04035876 2019-07-29
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
Zhejiang University
Phase 1/2 Unknown
NCT02759601 2018-12-20
CHR-2845
Queen Mary University of London
Phase 1/2 Unknown
NCT02942329 2018-02-26
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT03130712 2017-04-26
A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
Shanghai GeneChem Co., Ltd.
Phase 1/2 Unknown
NCT03124498 2017-04-21
A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA
Chuan An Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT03084380 2017-03-20
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
Xinqiao Hospital of Chongqing
Phase 1/2 Unknown
NCT03013712 2017-01-06
CARTEPC
First Affiliated Hospital of Chengdu Medical College
Phase 1/2 Unknown
NCT02839954 2016-12-06
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT02587689 2016-12-05
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT02959151 2016-11-08
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
Shanghai GeneChem Co., Ltd.
Phase 1/2 Unknown
NCT02886897 2016-09-01
A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors
Sun Yat-sen University
Phase 1/2 Unknown
NCT02772029 2016-05-13
A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Unknown
NCT02727309 2016-04-04
A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
Peking University Cancer Hospital & Institute
Phase 1/2 Unknown
NCT02715362 2016-03-22
GPC3-CART
Shanghai GeneChem Co., Ltd.
Phase 1/2 Unknown
NCT00553683 2014-01-14
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Unknown
NCT01392131 2012-12-12
Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)
Clinical Research Organization, Dhaka, Bangladesh
Phase 1/2 Unknown
NCT00999843 2009-10-22
Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
Fudan University
Phase 1/2 Unknown
NCT00390195 2009-07-02
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 1/2 Unknown
NCT00514930 2007-08-10
Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the Liver
University of Thessaly
Phase 1/2 Unknown
NCT00155272 2005-09-12
Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 1/2 Unknown
NCT00057395 2005-06-24
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
Aronex Pharmaceuticals
Phase 1/2 Unknown